World
CONTACTAbout UsCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2025 Equal Entertainment LLC.
All Rights reserved
All Rights reserved
By continuing to use our site, you agree to our Private Policy and Terms of Use.
Boehringer Ingelheim launches expanded access for Tipranavir
Drugmaker Boehringer Ingelheim on Tuesday announced the launch of an expanded access program for its experimental protease inhibitor Tipranavir. The program provides access to the drug for all treatment-experienced HIV patients not enrolled in the ongoing clinical study of Tipranavir who have demonstrated resistance to other protease inhibitors. Eligibility for the program is not limited by CD4-cell counts or HIV viral loads. Tipranavir is currently in Phase III studies and was submitted to the Food and Drug Administration for marketing approval in late October. A decision by the FDA is expected by April. Tipranavir is a nonpeptidic drug, unlike other protease inhibitors, giving it a unique resistance profile and making it effective for most HIV patients resistant to other protease drugs. For more information about the expanded access program, health care providers can call (888) 524-8675 or go online to www.tpv-eap.com.
Recommended Stories for You
From our Sponsors
Most Popular
More Videos
0 seconds of 1 minute, 20 secondsVolume 0%
Press shift question mark to access a list of keyboard shortcuts
Keyboard Shortcuts
Shortcuts Open/Close/ or ?
Play/PauseSPACE
Increase Volume↑
Decrease Volume↓
Seek Forward→
Seek Backward←
Captions On/Offc
Fullscreen/Exit Fullscreenf
Mute/Unmutem
Decrease Caption Size-
Increase Caption Size+ or =
Seek %0-9
Copied
Live
00:00
01:20
01:20
Latest Stories
Paris unveils memorial to LGBTQ+ victims of Nazi atrocities
May 19 2025 3:09 PM
Retired lesbian firefighter wins PTSD disability suit after years of abuse
May 19 2025 10:38 AM
Remembering Frank Kameny: Here's why he was a pioneer in gay rights
May 20 2025 5:30 AM
Top 11 LGBTQ+ true crime docs and how to watch them
May 19 2025 8:50 AM